BML-278
BML-278 is a SIRT1 activator (EC150: 1 μM) . BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts[1][2].
Product Specifications
CAS Number
120533-76-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Histone Methyltransferase; Sirtuin
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bml-278.html
Concentration
10mM
Purity
98.49
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CCOC(C1=CN(C=C(C(OCC)=O)C1C2=CC=CC=C2)CC3=CC=CC=C3)=O
Molecular Formula
C24H25NO4
Molecular Weight
391.46
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
